Histofy, a biomedical technology company specialising in AI solutions for pathology, proudly announces a partnership with Indica Labs, a leader in AI-powered image analysis and collaborative image management platforms. This strategic alliance marks a significant milestone, aiming to seamlessly integrate Histofy’s advanced AI tools into the HALO AP® platform, developed by Indica Labs.
Birmingham, UK and Albuquerque, NM, US (3 June 2024) – Indica Labs and Histofy have come together in a collaboration aimed at bringing Histofy’s cutting-edge AI tools into clinical practice via the established HALO AP® platform1. The partnership facilitates the integration of Histofy tools into clinical practice, placing cutting-edge AI in the hands of pathologists.
HALO AP® is an AI-powered, pathologist-driven diagnostic pathology platform that enables primary diagnosis and other routine workflows in anatomic pathology with a CE-IVDR mark in the EU, Switzerland, and the UK, demonstrating its compliance with key regulatory standards. Similarly, HALO AP Dx2 is a pathologist-centric platform that has recently obtained FDA clearance for primary diagnosis in the United States.
"We are thrilled to partner with Histofy to bring additional state-of-the-art AI solutions to our HALO AP® platform"
“At Histofy, we are committed to advancing the field of pathology through innovative AI technologies,” remarked Dr Simon Graham, CTO at Histofy. “The integration of Histofy’s AI tools into HALO AP® holds great promise for the pathology community. By seamlessly integrating with HALO AP®, Histofy’s tools will augment clinical workflows, empowering pathologists with enhanced diagnostic capabilities and efficiency gains.”
“We are thrilled to partner with Histofy to bring additional state-of-the-art AI solutions to our HALO AP® platform,” stated Eric Runde, Chief Operating Officer at Indica Labs. “This collaboration showcases our commitment to providing pathologists with cutting-edge tools for better patient care.”
The partnership between Histofy and Indica Labs represents a paradigm shift in pathology, leveraging the power of AI to revolutionise diagnostic processes and ultimately improve patient outcomes. As the healthcare landscape continues to evolve, this collaboration sets a precedent for future advancements in AI-driven pathology solutions.
1HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance and certifications with FDA 21 CFR Part 11, HIPAA, and GDPR.
2HALO AP Dx (K232833) is FDA-cleared for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the US. In addition, HALO AP Dx provides built-in compliance and certifications with FDA 21 CFR Part 11 and HIPAA.
About Histofy
Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care.
With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings.
About Indica Labs
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionises quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organisations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.
